Over the past few decades, the volume of data available to support drug and biological product development have increased substantially. These increases in data volume were also accompanied by an expansion in data diversity with data originating from …
Over the past few decades, the volume of data available to support drug and biological product development have increased substantially. These increases in data volume were also accompanied by an expansion in data diversity with data originating from …
Data sources and the volume of data available for driving discovery and informing decisions have substantially increased over time. This increase has resulted in an evolving data and regulatory landscape ripe for the expertise of statisticians and …
On Nov 22nd, 2021, the R Consortium R Submissions Working Group successfully submitted an R-based test submission package through the FDA eCTD gateway. The submission package has been received by the FDA staff who were able to reproduce the numerical …
The CDISC-SEND data standard has created new opportunities for collaborative development of open-source software solutions to facilitate cross-study analyses of toxicology study data. A public private partnership between BioCelerate and FDA/CDER was …
With recent technological advances and availability of new data sources, we are experiencing exciting changes to the human medical product regulatory landscape. While these new areas have created challenges, they also present opportunities. This …
The crisis of opioid abuse and overdose in the United States has involved unprecedented levels of opioid prescriptions and opioid-related mortality. Greater understanding of current trends in prescription opioid utilization may help prevent new cases …